Company intelligence / Profile preview

ZymIQ Technology

Lund, Skåne, Sweden

Ownership: Private
Development stage: Other

Overview

ZymIQ's enzyme technology demonstrates rapid and effective elimination of mycobacteria in preclinical in vivo models, including activity against dormant bacteria and synergy with antibiotics, indicating potential for faster and more efficient treatment of hard-to-treat bacterial infections compared to current standard therapies.[5]

Therapeutic areas: Infectious DiseasesDermatologyOther
Modalities: Enzyme-based therapyPhage-based therapy
Industry: Biotech

Drug pipeline

1 asset

ViruPrev

Preclinical

Partnerships

fjör (cosmetic applications)

Beyond the preview

Go deeper on ZymIQ Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZymIQ Technology.

Explore the full profile